📰 Xianping Lu News

Xianping Lu News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Xianping Lu. Real-time updates on events, politics, business and more.

National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma

April 30, 2024

/PRNewswire/ -- Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) announced that the companys lead innovative...

Feng Wang United States Ruihua Xu Sun Yat Xianping Lu Chidamide Tucidinostat

Source: prnewswire.com

Chidamide Plus R-CHOP Approved in China for MYC/BCL2–Expressing DLBCL

April 30, 2024

Chidamide plus R-CHOP has received approval from China’s NMPA for the management of diffuse large B-cell lymphoma.

Chipscreen Biosciences Xianping Lu China National Medical Products Administration Lymphoma International Prognosis Index Data Monitoring Committee National Medical Products Administration

Source: onclive.com

Biocytogen's Subsidiary Eucure Biopharma and Chipscreen Biosciences' Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008

February 27, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that its wholly owned subsidiary, Eucure (Beijing) Biopharma Co., Ltd. (“Eucure Biopharma”), has reached an exclusive licensing agreement with Chipscreen NewWay Biosciences (“Chipscreen NewWay”), a holding subsidiary of Shenzhen Chipscreen Biosciences Co., Ltd.

United States Hong Kong Baden Wüberg Haimen Jiangsu Chipscreen Newway Biosciences Chipscreen Biosciences

Source: businesswireindia.com

Chipscreen received a Phase 1b/2 clinical trial of Chiauranib/CS2164 IND clearance from the US Food and Drug Administration (FDA)

April 16, 2021

Chipscreen received a Phase 1b/2 clinical trial of Chiauranib/CS2164 IND clearance from the US Food and Drug Administration (FDA) News provided by Share this article SHENZHEN, China, April 16, 2021 /PRNewswire/ -- Shenzhen Chipscreen Biosciences, a China headquartered biopharmaceutical company developing and marketing novel drugs based on its unique technology of Chemical Genomics Drug discovery platform, today announces that it has received Investigational New Drug (IND) clearance from the...

United States Chipscreen Biosciences Auroab Vegfrs Xianping Lu Shenzhen Chipscreen Biosciences Ltd National Medical Products Administration

Source: prnewswire.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation